CliffBio
small molecule

DEFITELIO

DEFIBROTIDE SODIUM

Loss of exclusivityJune 2032latest FDA-listed patent expiry
CompanyJazz Pharmaceuticals →View the full company profile on CliffBio

Drug detail

Brand nameDEFITELIO
Active ingredientDEFIBROTIDE SODIUM
Strength200MG/2.5ML (80MG/ML)
Dosage formSOLUTION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalMarch 2016
Marketing statusRX

Listed patents

PatentExpiresType
11236328June 2032use U-3301
11085043June 2032product
12529052June 2032product
11746348June 2032product
12534722June 2032product

More from Jazz Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Not found